Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies
Diabetic Medicine · 2024
DOI: 10.1111/dme.15437 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetic Medicine, 2024. Verfasst von Shaghayegh Khanmohammadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Ir…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
While randomized controlled trials data on the long‐term effect of glucose‐lowering drugs (GLDs) on liver‐related outcomes are lacking, population‐based studies have evaluated the associations of GLDs with liver‐related outcomes in individuals with type 2 diabetes (T2D). we aimed to conduct a systematic review of population‐based studies evaluating the effects of GLDs on liver‐related outcomes in people with T2D.
Methods
PubMed, Web of Science, and Embase databases were systematically searched for population‐based studies testing the associations of GLDs with liver‐related outcomes in individuals with T2D and no liver disease other than non‐alcoholic fatty liver disease (NAFLD) from inception to 23 February 2024. GLDs included SGLT2is, TZDs, insulin, GLP‐1 RAs and dipeptidyl peptidase‐4 inhibitors (DPP4Is).
Results
Ten cohort studies, comprising 1,274,641 participants, met the inclusion criteria. The median follow‐up period ranged from 8.9 to 76 months. Of all the GLDs under investigation, SGLT2is were associated with the strongest reduction in NAFLD incidence, cirrhosis, and composite liver‐related events compared to other medications. TZDs were associated with a reduced risk of developing NAFLD and cirrhosis but were not significantly associated with a lower incidence of hepatocellular carcinoma. GLP‐1 RAs demonstrated a significant association with reduced liver‐related mortality.
Conclusions
Observational data from population‐based studies suggest that GLDs such as SGLT2is are associated with beneficial long‐term liver‐related outcomes in T2D patients with NAFLD. Additional studies, including randomized controlled trials with long‐term follow‐up, are needed to confirm these findings. Registration Number PROSPERO CRD442024536872.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
- Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
ORCID-Profile: Mohammad Shafi Kuchay
Zitieren
APA
Khanmohammadi, S., Habibzadeh, A., Kamrul-Hasan, A. B. M., Schuermans, A., & Kuchay, M. S. (2024). Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies. Diabetic Medicine. https://doi.org/10.1111/dme.15437
Vancouver
Khanmohammadi S, Habibzadeh A, Kamrul-Hasan ABM, Schuermans A, Kuchay MS. Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies. Diabetic Medicine. 2024. doi:10.1111/dme.15437
BibTeX
@article{Khanmohammadi2024,
author = {Khanmohammadi, Shaghayegh and Habibzadeh, Amirhossein and Kamrul-Hasan, A B M and Schuermans, Art and Kuchay, Mohammad Shafi},
title = {Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies},
journal = {Diabetic Medicine},
year = {2024},
doi = {10.1111/dme.15437}
}
EUVIMED